EGFR and non-small cell lung carcinoma: Although our patient had EGFR L858R mutation, she did not receive adjuvant osimertinib for her Stage IIIA NSCLC at diagnosis in 2019 because the results of the ADURA trial were published in October 2020, and FDA approval came in December 2020.